This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The approval bolsters the company's Mycophenolate Mofetil portfolio
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Subscribe To Our Newsletter & Stay Updated
